On Monday, Viracta Therapeutics Inc (NASDAQ: VIRX) was 10.60% up from the session before settling in for the closing price of $0.16. A 52-week range for VIRX has been $0.13 – $1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 134.94%. When this article was written, the company’s average yearly earnings per share was at 31.57%. With a float of $27.91 million, this company’s outstanding shares have now reached $39.74 million.
Considering the fact that the conglomerate employs 40 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 55.42%, operating margin of -6397.02%, and the pretax margin is -5865.72%.
Viracta Therapeutics Inc (VIRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Viracta Therapeutics Inc stocks. The insider ownership of Viracta Therapeutics Inc is 29.78%, while institutional ownership is 13.00%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares.
Viracta Therapeutics Inc (VIRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 31.57% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
You can see what Viracta Therapeutics Inc (VIRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Compared to the last year’s volume of 0.77 million, its volume of 12.51 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 42.27%. Additionally, its Average True Range was 0.02.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 9.52%, which indicates a significant decrease from 58.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.96% in the past 14 days, which was higher than the 87.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1965, while its 200-day Moving Average is $0.5275. Nevertheless, the first resistance level for the watch stands at $0.1951 in the near term. At $0.2159, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2420. If the price goes on to break the first support level at $0.1482, it is likely to go to the next support level at $0.1221. Should the price break the second support level, the third support level stands at $0.1013.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
There are 39,744K outstanding shares of the company, which has a market capitalization of 6.99 million. As of now, sales total 0 K while income totals -51,060 K. Its latest quarter income was 0 K while its last quarter net income were -10,550 K.
